肝细胞肝癌的免疫治疗基础和临床研究进展

原发性肝癌，特别是肝细胞肝癌，严重威胁我国人民的生命和健康。由于肝癌起病隐匿，首次诊断时只有不到30%的患者适合接受根治性治疗，系统抗肿瘤治疗在中晚期肝癌的治疗过程中发挥重要作用。近年来肝癌的免疫治疗飞速发展，越来越多的免疫治疗药物成为肝癌一线、二线治疗选择，较好地控制肝癌的进展，延长患者的生存时间。本文就近年来肝癌免疫治疗进展行简要综述。

Basic and Clinical Research Progress of Immunotherapy for Hepatocellular Carcinoma

Primary liver cancer, especially hepatocellular carcinoma, poses a serious threat to the life and health of the Chinese people. Given the insidious onset of liver cancer, less than 30% of hepatocellular carcinoma patients are considered for radical treatment at the initial diagnosis. Systemic anti-tumor therapy plays an important role in the treatment of advanced hepatocellular carcinoma. Immunotherapy of hepatocellular carcinoma has developed rapidly, and an increasing number of immunotherapy drugs, which can better control the progress of hepatocellular carcinoma and prolong the survival of patients, have become first-and second-line treatment options. This article reviews briefly the progress of immunotherapy for hepatocellular carcinoma in recent years. © 2023, CHINA RESEARCH ON PREVENTION AND TREATMENT. All rights reserved.